Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castrate-resistant prostate cancer: a pooled analysis.
Journal: The oncologist
Published: February 22, 2026
Prevalence of adverse events following T-cell redirecting therapies in patients with metastatic castration-resistant prostate cancer: a pooled analysis.
Journal: The oncologist
Published: February 22, 2026
B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 09, 2026
Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4+CD8+ T cells.
Journal: Cell reports. Medicine
Published: December 30, 2025
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager.
Journal: Neuro-oncology
Published: October 07, 2025
Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors.
Journal: Cancer immunology research
Published: October 03, 2025
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer.
Journal: Cancer chemotherapy and pharmacology
Published: August 26, 2025
Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients.
Journal: Cell reports. Medicine
Published: August 15, 2025
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes.
Journal: Prostate cancer and prostatic diseases
Published: August 12, 2025
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.
Journal: Journal for immunotherapy of cancer
Published: July 10, 2025
HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: May 23, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting.
Journal: Cancer research communications
Published: September 25, 2024
Last Updated: 09/26/2026